{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.","groups":[{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n* Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle.\n* Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG000","title":"Part C Cohort C1"}],"paramType":"NUMBER","populationDescription":"All part C participants who received at least one dose of study drug. However, Part C was terminated early and only 1 participant was enrolled in this part.","reportingStatus":"POSTED","timeFrame":"Date of first dose to progressive disease or death (Up to 25 Months)","title":"Progression-Free Survival (PFS): Part C","type":"SECONDARY","unitOfMeasure":"Months"}